Novo Nordisk’s ADA Data: One Success, One Setback, and a Stock Under Pressure
Novo Nordisk shares drop 16% YTD after CagriSema fails non-inferiority vs Lilly’s Zepbound; Zenagamtide Phase 2 shows strong…
Novo Nordisk’s Dual Narrative: Factory Start-Up and Pipeline Showdown at ADA
Novo Nordisk opens a Czech GLP-1 plant on June 12 and presents critical CagriSema data at ADA as…
Novo Nordisk at a Crossroads: Pipeline Hopes Meet Pricing Pressures Ahead of ADA and Medicare Shift
New semaglutide kidney data boosts pipeline confidence, but CVS formulary changes and discounted Medicare pricing pressure margins, sending…
Novo Nordisk’s Buyback Program Hits 4.7 Billion Kronen as ADA Conference Holds the Next Catalyst
Novo Nordisk spent €4.7B on share buybacks but stock is down 40% YoY. Revenue growth was artificial, US…
Novo Nordisk’s Stock Hinges on ADA Data as US Reimbursement Window Narrows
Novo Nordisk presents CagriSema and zenagamtide data at ADA, while CVS Caremark ends Wegovy’s exclusive formulary status, intensifying…
Novo Nordisk’s Brazilian Generic Setback Adds Urgency to ADA Pipeline Showcase
Brazil approves first generic Ozempic at 30% discount; Novo cuts Canada prices. All eyes on CagriSema Phase 3…